Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11520 posts found.

FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis

October 30, 2019 Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma

The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …
News

Expanded EU label for Benlyta now covers paediatric lupus patients

October 30, 2019 Research and Development, Sales and Marketing Benlyta, Europe, GSK, Lupus, pharma

GlaxoSmithKline is celebrating the news that the European Commission has chosen to approve an expansion to the label of its …
News

European Commission approves Sanofi’s Dupixent in chronic rhinosinusitis with nasal polyposis

October 30, 2019 Research and Development, Sales and Marketing Dupixent, EU, Sanofi, pharma

Sanofi’s Dupixent (dupilumab) has secured European approval for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), it has emerged. …
News
credit_-_daniel_leal-olivas-afp

Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer

October 29, 2019 Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …
News
shutterstock_339308225

Deeper patient insights for stronger patient outcomes

October 28, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing eyeforpharma, pharma

Patient insights are crucial. As you already know, they are the key to the creation of successful, targeted programmes and …
News
gilead-sciences

Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome

October 28, 2019 Research and Development, Sales and Marketing Gilead, Lupus, filgotinib, pharma

Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment of rheumatoid arthritis has been …
News
shutter

UKRI and BBSRC award £170m to 3 UK universities for biotech and biology PhD studentships

October 28, 2019 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UK, pharma, research

The Biotechnology and Biological Sciences Research Council (BBSRC) and UK Research and Innovation (UKRI) have awarded a funding injection of …
News
shutterstock_138095450

Ovarian cancer market set to smash $6.7 billion by 2025

October 28, 2019 Sales and Marketing Cancer, GlobalData, ovarian cancer, pharma

New research from GlobalData has forecast that the worldwide market for ovarian cancer is set to expand at a compound …
News
flag-map_of_nigeria

Almost 400 Nigerian medical dispensaries shut down for sub-standard practice

October 28, 2019 Manufacturing and Production, Medical Communications, Sales and Marketing Nigeria, pharma

Nigeria has seen almost 400 of its medicine dispensaries shut down over “unethical practices and lack of compliance, it has …
News

European approval announced for Astellas’ Xospata in FLT3+ treatment-resistant acute myeloid leukaemia

October 28, 2019 Sales and Marketing Astellas, Xospata, leukaemia, pharma

Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for …
News
top_10_photo

Top Ten most popular articles on Pharmafile.com this week

October 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

It’s another end of the week here at Pharmafile and here we run down our top 10 articles and features …
News

FlyPharma tackles supply chain challenges and industry best practice at another successful conference

October 24, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flypharma, pharma

For its fifth annual Europe conference, FlyPharma chose Copenhagen as its host city to address the latest supply chain challenges …
News
alkermes

Alkermes to axe 160 jobs in cost-cutting restructure

October 24, 2019 Sales and Marketing

The Irish biopharma company expects to complete most of the job cuts by end of this year and will take …
News
222170359

Damage control: How will pharma manage the health economic impacts of Brexit?

October 23, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HEOR, brexit, health economics and outcomes research, pharma

When it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the …
Feature
vertex-headquarters

FDA approves Vertex’s Trikafta in new indication, now potentially covering 90% of cystic fibrosis patients

October 23, 2019 Research and Development, Sales and Marketing FDA, Trikafta, Vertex, cystic fibrosis, pharma

The FDA has granted marketing authorisation to Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), it …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025